title: HER2-negative (1+) breast cancer with unfavorable prognostic features: to FISH or not to FISH?
authors.affiliation: Research Unit in Medical Senology, Department of Medicine, European Institute of Oncology, Milan. Electronic address: monica.iorfida@ieo.it.
authors.forename: M
authors.initials: M
authors.lastname: Iorfida
authors.affiliation: Research Unit in Medical Senology, Department of Medicine, European Institute of Oncology, Milan.
authors.forename: S
authors.initials: S
authors.lastname: Dellapasqua
authors.affiliation: Division of Epidemiology and Biostatistics, European Institute of Oncology, Milan.
authors.forename: V
authors.initials: V
authors.lastname: Bagnardi
authors.affiliation: Research Unit in Medical Senology, Department of Medicine, European Institute of Oncology, Milan.
authors.forename: A
authors.initials: A
authors.lastname: Cardillo
authors.affiliation: Division of Epidemiology and Biostatistics, European Institute of Oncology, Milan.
authors.forename: N
authors.initials: N
authors.lastname: Rotmensz
authors.affiliation: Division of Pathology, European Institute of Oncology and University of Milan School of Medicine, Milan.
authors.forename: M G
authors.initials: MG
authors.lastname: Mastropasqua
authors.affiliation: Division of Pathology, European Institute of Oncology and University of Milan School of Medicine, Milan.
authors.forename: L
authors.initials: L
authors.lastname: Bottiglieri
authors.affiliation: Department of Medicine, European Institute of Oncology, Milan, Italy.
authors.forename: A
authors.initials: A
authors.lastname: Goldhirsch
authors.affiliation: Division of Pathology, European Institute of Oncology and University of Milan School of Medicine, Milan.
authors.forename: G
authors.initials: G
authors.lastname: Viale
authors.affiliation: Research Unit in Medical Senology, Department of Medicine, European Institute of Oncology, Milan.
authors.forename: M
authors.initials: M
authors.lastname: Colleoni
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000175:diagnosis* / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D002277:Carcinoma / Q000175:diagnosis* / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D005260:Female; D005784:Gene Amplification / Q000502:physiology; D005787:Gene Frequency; D006801:Humans; D017404:In Situ Hybridization, Fluorescence / Q000706:statistics & numerical data*; D058990:Molecular Targeted Therapy / Q000379:methods / Q000706:statistics & numerical data; D008991:Monitoring, Physiologic / Q000379:methods; D009361:Neoplasm Invasiveness; D011379:Prognosis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism*; D000068878:Trastuzumab
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab; C508053:ERBB2 protein, human